Read this manager's filing book
Disclosed positions
Lynx1 Capital Management LP: source evidence dated 2026-08-14T03:59:59.999Z.
- Issuer
- GH RESEARCH PLC
- Ticker
- GHRS
- Class
- ORDINARY SHARES
- Reported value
- $356,517,181
- Reported amount
- 13,263,288
- Unit
- SH
- Option
- None
The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.
What was reported for this quarter?
13F positions are dated quarter-end holdings, with later publication and possible amendments. Read report period and availability before calling them current.
SEC 13F-HR/A: 0001910456-26-000004Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filings
Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filingsKeep reporting dates and units beside the answer, and inspect its original citations.
Disclosed positions
See the complete disclosed positions
| GH RESEARCH PLC | GHRS | ORDINARY SHARES | $356,517,181 | 13,263,288 | SH | None |
| CULLINAN THERAPEUTICS INC | CGEM | COM | $163,225,335 | 8,963,500 | SH | None |
| STOKE THERAPEUTICS INC | STOK | COM | $132,136,579 | 4,038,404 | SH | None |
| AGIOS PHARMACEUTICALS INC | AGIO | COM | $126,505,652 | 3,408,937 | SH | None |
| C4 THERAPEUTICS INC | CCCC | COM STK | $34,215,647 | 7,326,691 | SH | None |
| KORRO BIO INC | KRRO | COM | $20,274,741 | 1,538,296 | SH | None |
| TSCAN THERAPEUTICS INC | TCRX | COM | $7,859,567 | 8,019,148 | SH | None |
| PRECISION BIOSCIENCES INC | DTIL | COM NEW | $7,470,663 | 950,466 | SH | None |
| NEUPHORIA THERAPEUTICS INC | NEUP | COM | $3,825,183 | 875,328 | SH | None |
| PASSAGE BIO INC | PASG | COM NEW | $3,287,942 | 673,759 | SH | None |
| CG ONCOLOGY INC | CGON | COM | $2,230,331 | 31,391 | SH | None |
| PLIANT THERAPEUTICS INC | PLRX | COM | $2,049,800 | 1,798,070 | SH | None |
| ENTRADA THERAPEUTICS INC | TRDA | COM | $1,314,540 | 178,606 | SH | None |
| VYNE THERAPEUTICS INC | Unresolved | COM | $1,059,795 | 1,628,700 | SH | None |
| PROQR THRAPEUTICS N V | PRQR | SHS EURO | $969,828 | 521,413 | SH | None |
| TRAWS PHARMA INC | TRAW | COM NEW | $471,801 | 559,470 | SH | None |
| FOGHORN THERAPEUTICS INC | FHTX | COM | $300,549 | 61,588 | SH | None |
| DENALI THERAPEUTICS INC | DNLI | COM | $299,844 | 11,658 | SH | None |
| XENCOR INC | XNCR | COM | $292,923 | 18,194 | SH | None |
| ABSCI CORPORATION | ABSI | COM | $246,230 | 21,245 | SH | None |
| WEREWOLF THERAPEUTICS INC | HOWL | COM | $236,737 | 657,786 | SH | None |
| IMMATICS N.V | IMTX | SHS | $235,381 | 23,236 | SH | None |
| AVALO THERAPEUTICS INC | AVTX | COM NEW | $186,648 | 10,100 | SH | None |
| BOLT BIOTHERAPEUTICS INC | BOLT | COM NEW | $118,580 | 30,800 | SH | None |
| NUVATION BIO INC | NUVB | COM CL A | $91,045 | 16,029 | SH | None |
| EUPRAXIA PHARMACEUTICALS INC | EPRX | COM | $66,100 | 10,000 | SH | None |
| INHIBIKASE THERAPEUTICS INC | IKT | COM NEW | $40,600 | 20,000 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 1 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.